KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Vipul Jairath, Fernando Magro, Marijana Protic, Gert De Hertogh, Noam Harpaz, Tadakazu Hisamatsu, Geert D'Haens, Rish Pai, Guanglei Yu, Nathan Morris, Wen Tao Luo, Emily Hon, Rodrigo Escobar, Luc Biedermann, Walter Reinisch, VIVID Study Group

J Crohns Colitis 20(6) jjag077

PMID42309525
PMCIDPMC13275131
DOI10.1093/ecco-jcc/jjag077
发表日期2026-06-17
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 other;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图;另有 1 张未列出。
摘要

摘要

BACKGROUND AND AIMS: Evaluation of microscopic inflammation is an emerging therapeutic target of Crohn's disease. The completed VIVID-1 trial evaluated histologic and combined histologic-endoscopic outcomes for mirikizumab relative to placebo and ustekinumab in moderately-to-severely active Crohn's disease. METHODS: Two specimens from each of five intestinal segments (one ileal, four colonic) were obtained from the edge of ulcers, or the most inflamed mucosa at screening, and weeks (W)12 and 52. Histologic response was defined as the absence of epithelial neutrophils and epithelial damage, erosions and ulceration or ≥50% decrease in either the active Robarts Histopathology Index or the active Global Histologic Disease Activity Score, and was prespecified. Histologic remission was defined as absence of mucosal neutrophils, no epithelial damage, and no erosions and ulcers and was a prespecified endpoint. Post-hoc analyses included subgroup analyses, the proportions of patients achieving combined histologic-endoscopic outcomes, the agreement between histologic outcomes and endoscopic or clinical outcomes, segmental analyses, the assessment of cut-off points for fecal calprotectin, and the association between W12 histologic outcomes and selected W52 outcomes. RESULTS: At W12, mirikizumab was superior to placebo for histologic response (P < .0001) and histologic remission (P = .001), with similar rates to ustekinumab (P = .58 and P = .44, respectively). At W52, mirikizumab-treated patients showed greater histologic response (P = .008) compared to ustekinumab, especially in patients who previously failed biologic therapies (P = .006). Combined histologic-endoscopic response at W52 was numerically higher for mirikizumab (P = .06) and reached statistical significance among biologic-failed patients (P = .02); however, combined remission rates were comparable across treatment arms. CONCLUSIONS: Mirikizumab was superior to placebo in achievement of all histology-based endpoints. Mirikizumab showed higher rates compared to ustekinumab for achievement of histologic response at W52. Early histologic response among endoscopic non-responders was associated with 1-year endoscopic outcomes. ClinicalTrials.gov, NCT03926130.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Histologic response (A) and remission (B) at Week 12 among all patients in the prespecified population, and histologic response (C) and remission (D) at Week 12 among patients with active histologic disease at baseline. *All patients were from all randomized patients who received ≥1 dose of allocated treatment with baseline SES-CD ≥ 7 (or ≥4 for isolated ileal disease) (primary analysis set). Analyses in *All patients were prespecified, non-multiplicity-controlled endpoints. Analyses in Endoscopic Response and Clinical Response by PRO are both multiplicity controlled. Abbreviations: PBO, placebo; MIRI, mirikizumab; USTE, ustekinumab.
非 KM Figure
Figure 2.Ranking of predictor importance with Week 12 histologic response (A) and histologic remission (B) based on multivariable logistic regression. The x -axis is represented as chi-squared minus degrees of freedom (df), which indicates the strength of the predictor variable’s impact on the outcome and its explanatory power in the model. A larger value of Wald chi-square minus df indicates a higher importance of the predictor, meaning it provides more explanatory power to the model. Corresponding P -values <.05 indicate that the predictor variable contributes significantly to the model. Abbreviations: RHI, Robarts Histopathology Index; CRP, C-reactive protein; CDAI, Crohn’s disease Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
非 KM Figure
Figure 3.Histologic response among all patients in the prespecified population at Week 52 (A) and combined histologic–endoscopic response at Week 52: (A) histological response all patients, (B) with and without biologic failure, and (C) histologic–endoscopic response for all patients with and without biologic failure who had active disease at baseline. *** P < .001: P -values for “All patients” and “All active patients” were from the Cochran–Mantel–Haenszel test adjusting for baseline covariates; Analyses in *Patients with prior biologic failure or *Patients without prior biologic failure” were post-hoc. Participants who were randomized to PBO and switched to MIRI at Week 12 were treated as nonresponders at Week 52. Abbreviations: MIRI, mirikizumab; PBO, placebo; USTE, ustekinumab; n, number of patients in the specified category; N, number of patients in the analysis population.
非 KM Figure
Figure 4.Week 52: (A) Histological remission all patients, (B) histologic remission with and without biologic failure, and (C) histologic–endoscopic remission for all patients with and without biologic failure who had active disease at baseline. ** P < .001: P -values for “All patients” and “All patients with active disease” were from the Cochran–Mantel–Haenszel test adjusting for baseline covariates. Analyses in *Patients with prior biologic failure or *Patients without prior biologic failure were post-hoc. Participants who were randomized to PBO and switched to MIRI at Week 12 were treated as nonresponders at Week 52. Abbreviations: CI, confidence interval; MIRI, mirikizumab; PBO, placebo; USTE, ustekinumab; n, number of patients in the specified category; N, number of patients in the analysis population.
非 KM Figure
Figure 5.Change in RHI score from baseline per segment (A), histologic response (B), and histologic remission (C) at Week 52. Patients with active histologic disease at baseline were included in this analysis. Abbreviations: MIRI, mirikizumab; PBO, placebo; USTE, ustekinumab; LSM, least square means; n, number of patients in the specified category; N, number of patients in the analysis population; RHI, Robarts Histopathology Index.
非 KM Figure
Figure 6.Histologic images. Images are 40× magnification. Scale bar is 60µm. Arrows indicate neutrophils. (A) Active histologic disease at baseline in the transverse colon of a patient randomized to placebo; neutrophil infiltration of epithelium and lamina propria, dense chronic inflammatory infiltrate; crypt abscess in the center of the image. (B) Active histologic disease at week 12 in the transverse colon of a patient treated with placebo; neutrophil infiltration of epithelium and lamina propria with epithelial damage and dense chronic inflammatory infiltrate. (C) Active histologic disease at week 52 in in the transverse colon of a patient treated with placebo; neutrophil infiltration of epithelium and lamina propria, dense chronic inflammatory infiltrate. (D) Active histologic disease at baseline in the transverse colon of a patient randomized to mirikizumab; neutrophil infiltration of epithelium and lamina propria and dense chronic inflammatory infiltrate. (E) Histologic response at week 12 in the transverse colon of a patient treated with mirikizumab; some rare neutrophils in crypts and chronic inflammatory infiltrate. (F) Histologic remission at week 52 in the transverse colon of a patient treated with mirikizumab; no epithelial or lamina propria neutrophils, some rare chronic inflammatory infiltrate.
非 KM Figure